AAVid gene-therapy collaboration with Shape TX

Otsuka Pharmaceutical and Shape TX announced a multi-target collaboration to develop intravitreally delivered AAVs for ocular diseases. The release describes Shape TX's AI-driven AAVid platform as combining screening of billions of AAV variants with machine learning to identify novel capsids, and says Shape TX is eligible for payments potentially exceeding $1.5 billion.